title: [Advanced glycation end products: A risk factor for human health].
abstract: Advanced glycation end products (AGE) result from a chemical reaction between the carbonyl group of reducing sugar and the nucleophilic NH2 of a free amino acid or a protein; lysine and arginine being the main reactive amino acids on proteins. Following this first step, a molecular rearrangement occurs, rearrangement of Amadori resulting to the formation of Maillard products. Glycation can cause the clouding of the lens by inducing reactions crosslinking proteins. Specialized receptors (RAGE, Galectin 3…) bind AGE. The binding to the receptor causes the formation of free radicals, which have a deleterious effect because they are powerful oxidizing agents, but also play the role of intracellular messenger, altering the cell functions. This is especially true at the level of endothelial cells: the attachment of AGE to RAGE receptor causes an increase in vascular permeability. AGE binding to endothelium RAGE and to monocytes-macrophages, led to the production of cytokines, growth factors, to the expression of adhesion molecules, and the production of procoagulant activity. Diabetic retinopathy is related to excessive secretion of vascular growth factor (vascular endothelial growth factor [VEGF]). AGE-RAGE receptor binding causes the synthesis and secretion of VEGF. Increased permeability, facilitation of leukocyte migration, the production of reactive oxygen species, cytokines and VEGF suggest that the AGE could be an element of a cascade of reactions responsible for the diabetic angiopathy and vascular damages observed during aging and chronic renal failure. Balanced diet or some drugs can limit the deleterious effect of AGE.
authors.affiliation: Faculté de médecine, université Denis-Diderot Paris 7, 8, avenue Léopold-II, 75016 Paris, France.
authors.forename: M-P
authors.initials: MP
authors.lastname: Wautier
authors.affiliation: Unité EGEAL, institut polytechnique LaSalle-Beauvais, rue Pierre-Waguet, 60026 Beauvais, France.
authors.forename: F J
authors.initials: FJ
authors.lastname: Tessier
authors.affiliation: Faculté de médecine, université Denis-Diderot Paris 7, 8, avenue Léopold-II, 75016 Paris, France. Electronic address: jlwautier@hotmail.fr.
authors.forename: J-L
authors.initials: JL
authors.lastname: Wautier
mesh_terms: D017127:Glycation End Products, Advanced / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D000067759:Receptor for Advanced Glycation End Products / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors
chemical_list: C000593871:AGER protein, human; D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products
keywords: Advanced glycation end products; Cytokines; Diabetes; Diabète; Endothelium; Endothélium; Maillard; Perméabilité vasculaire; Produits de glycation avancée; Vascular permeability